RICOH-EUROPE
4.11.2015 10:02:08 CET | Business Wire | Press release
The overwhelming majority of businesses across Europe (92 per cent) admit they are not ready for the introduction of the EU Digital Single Market, according to new research commissioned by Ricoh Europe . The Digital Single Market is set to be the most game-changing European regulation this decade, yet millions of businesses currently stand to miss out on its benefits and let an estimated €415bn contribution to the European economy pass them by1 .
Only half of businesses (51 per cent) have heard of the EU’s proposed Digital Single Market, which is due to come into force at the end of 2016 and will standardise Europe’s online marketplace so that the same content, products and services are available at the same prices anywhere in the EU. Awareness of the proposals is at its lowest in The Nordics (28 per cent), Belgium/Luxembourg (29 per cent) and Portugal (30 per cent), according to the survey of 1,360 business leaders from across EU states.
| # | Percentage of businesses in each country aware of the EU’s Digital Single Market | # | Percentage of businesses in each country not ready for Digital Single Market | |||||||||
| 1. | Italy | 70% | 1. | Poland | 97% | |||||||
| - | France | 70% | 2. | France | 95% | |||||||
| 2. | Spain | 65% | - | Germany | 95% | |||||||
| 3. | Germany | 61% | 3. | Belgium / Luxembourg | 94% | |||||||
| 4. | UK | 57% | 4. | UK | 92% | |||||||
| 5. | Poland | 47% | - | Spain | 92% | |||||||
| - | Austria | 47% | - | Portugal | 92% | |||||||
| 6. | Hungary | 46% | 5. | Hungary | 91% | |||||||
| 7. | The Netherlands | 43% | 6. | Italy | 91% | |||||||
| 8. | Portugal | 30% | 7. | The Nordics | 90% | |||||||
| 9. | Belgium / Luxembourg | 29% | 8. | Austria | 88% | |||||||
| 10. | The Nordics | 28% | 9. | The Netherlands | 86% | |||||||
The low levels of awareness and preparation are particularly worrying given that only seven per cent of EU SMEs currently sell across borders; a figure which needs to be increased if the European economy is to thrive2 . Most European businesses (65 per cent) say they intend to expand to other countries in the continent over the next five years, but unless they embrace the Digital Single Market these ambitious growth plans are unlikely to be realised. Companies from the Austria, Hungary and The Nordics are the most likely to have plans to expand outside of their own country by 2020.
Most respondents thought that there would be several benefits from a digital single market, in particular, an increase in the number of customers from the EU (chosen by 56 per cent of respondents), the opportunity to access new European markets (chosen by 52 per cent), as well as increased internal efficiency in their own business (44 per cent).
However, 24 per cent of companies surveyed don’t believe there will be any benefits resulting from a digital single market, and many have concerns about its impact on their business. 40 per cent of businesses claim they are not ready for the increased competition a digital single market will introduce, while 37 per cent are afraid of its cost implications, and 34 per cent believe they lack the resources to capitalise on the opportunity. A third also believes there will only be more regulation for the sake of it.
| Perceived benefits to the business | Perceived concerns for the business | ||||||
| Increased EU customers | 56% | Increased competition | 42% | ||||
| Reduced barrier to enter new markets | 52% | Greater IT requirements | 41% | ||||
| Greater revenue | 52% | VAT obstacles | 36% | ||||
| Greater profitability | 50% | Cross border data protection uncertainty | 34% | ||||
| Reduced operating costs | 48% | Investment required to launch in a new territory | 34% | ||||
| Faster launch of new products/services | 47% | Prices of products and/or services driven down | 32% | ||||
| More efficient internal processes and systems | 44% | Lack of clear cross-border e-commerce rules | 29% | ||||
David Mills, CEO of Ricoh Europe , said: “So far, business leaders are failing to grasp the enormous impact the impending Digital Single Market will have upon their company. It’s a genuine concern that many bosses appear to feel no immediate pressure to prepare their organisations for Europe’s shift towards an increasingly digitally-based economy.”
One reason for companies’ lack of excitement about the Digital Single Market might be their concerns about their own countries’ digital strength. Only nine per cent of European business leaders say their own country is “very strong” at digital technology, skills and infrastructure. Whilst nearly two-thirds of businesses in the Nordics believe their countries are digitally strong, this shrinks to a fifth of Polish and Spanish companies, and only 15 per cent of those in France and Italy. According to the European Commission’s Digital Economy and Society Index3 , Denmark, Sweden and Finland rank as the top three digitally-enabled nations out of the 28 EU Member States with both Poland, Italy and Spain listed in the bottom half.
Mills continues: “By starting to streamline, digitise and standardise their processes now, forward-thinking European businesses will be in good stead to develop a distinct competitive advantage. This is a necessary step if Europe is going to create home-grown digital giants that can compete on the global stage traditionally dominated by American, and increasingly Chinese, companies.”
Find out more at www.ricoh-europe.com/thoughtleadership .
-ends-
1 http://ec.europa.eu/priorities/digital-single-market/
2 http://europa.eu/rapid/press-release_IP-15-4919_en.htm
3 http://europa.eu/rapid/press-release_IP-15-4475_en.htm
About Ricoh
Ricoh is a global technology company specializing in office imaging equipment, production print solutions, document management systems and IT services. Headquartered in Tokyo, Ricoh Group operates in about 200 countries and regions. In the financial year ending March 2015, Ricoh Group had worldwide sales of 2,231 billion yen (approx. 18.5 billion USD).
The majority of the company's revenue comes from products, solutions and services that improve the interaction between people and information. Ricoh also produces award-winning digital cameras and specialized industrial products. It is known for the quality of its technology, the exceptional standard of its customer service and sustainability initiatives.
Under its corporate tagline, imagine. change. Ricoh helps companies transform the way they work and harness the collective imagination of their employees.
For further information, please visit www.ricoh-europe.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20151104005002/en/
Contact:
For further information, please contact:
Ricoh Europe PLC
Jack
Gibson / Lakshmi Rajendran
Tel: +44 (0) 203 033 3766
E-mail: press@ricoh-europe.com
Homepage: www.ricoh-europe.com
Join
us on Facebook: www.facebook.com/ricoheurope
Follow
us on Twitter: www.twitter.com/ricoheurope
Visit
the Ricoh media centre at: www.ricoh-europe.com/press
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
